OUTSOURCED PHARMA CAPACITY UPDATE SMALL MOLECULE VIDEOS
Rottendorf Pharma Capabilities Update October 2026: Small Molecule Drug Product
Optimize oral solid dose development with scalable formulations, robust process engineering, and integrated supply networks that accelerate scale-up and ensure reliable market delivery.
Morpho Alfasigma Capabilities Update October 2026: Small Molecule Drug Product
Scale-up small molecule therapies with seamless tech transfer, regulatory alignment, and commercial manufacturing expertise for reliable, high-quality drug delivery.
Novartis Capabilities Update October 2026: Small Molecule Drug Substance
Scaling small molecule production demands flexible capacity, specialized chemistry, and seamless tech transfer. High-containment manufacturing supports reliable supply from clinic to commercial.
Bora Pharmaceuticals Capabilities Update October 2026: Small Molecule Drug Product
Simplify outsourcing across diverse pipelines with flexible dosage-form capabilities, scalable capacity, and support from clinical development to commercial supply.
SK Pharmteco Capabilities Update October 2026: Small Molecule Drug Substance
Backed by decades of experience and a proven track record of quality, this organization deliver programs from early-phase to commercial manufacturing.
Siegfried Capabilities Update October 2026: Small Molecule Drug Substance
Siegfried supports small molecules from development through commercialization with scalable processes and a global network built for reliable, secure supply.
Flamma Capabilities Update October 2026: Small Molecule Drug Substance
Discover how new approaches to API and peptide development can improve process control, repeatability, efficiency, and manufacturing readiness.
Upperton Pharma Solutions Capabilities Update April 2026: Small Molecule Drug Product
Learn more about UK-CDMO, Upperton Pharma Solutions, and their expertise across oral, nasal, pulmonary and sterile drug product development and manufacturing
Thermo Fisher Scientific Capabilities Update April 2026: Small Molecule Drug Product
Align formulation, process, and scale strategy early to support larger batches, new equipment, and commercial manufacturing — cutting rework and speeding Phase I to launch.
From Formulation To Commercial Supply: Advancing Small Molecule Therapies
We assist pharmaceutical and biotechnology companies with their contract manufacturing and development needs, specializing in high-potency softgels and liquids.
Bora Pharmaceuticals Capabilities Update April 2026: Small Molecule Drug Product
Bora Pharmaceuticals is a global CDMO specializing in small molecule drug product development and manufacturing from clinical through commercial supply.
Adare Pharma Solutions Capabilities Update April 2026: Small Molecule Drug Product
With a proven history in drug delivery, Adare’s facilities in the US and Europe have developed and manufactured more than 65 products sold by customers worldwide.
Quotient Sciences Capabilities Update March 2026: Small Molecule Drug Product
This session is designed to help you assess which development approaches, locations, and timelines may be most appropriate for your asset.
Pfizer CentreOne Capabilities Update March 2026: Small Molecule Drug Product
From development through commercial supply, our integrated capabilities and rigorous quality standards ensure reliable execution and consistent performance at every stage.
PCI Pharma Services Capabilities Update March 2026: Small Molecule Drug Product
Gain insight into our SMART FHD™ approach, designed to accelerate early-phase development through streamlined first-human-dose readiness, as well as its integrated partner network for targeted protein degraders (TPDs).
Mikart Capabilities Update March 2026: Small Molecule Drug Product
Discover how integrated formulation development, scalable manufacturing, and robust facility infrastructure can streamline your small molecule programs from early development through commercial production with confidence.
Asymchem Capabilities Update March 2026: Small Molecule Drug Product
Guided by a technology-driven approach and supported by a highly coordinated development and manufacturing ecosystem, we provide high-quality, efficient drug product solutions aligned with stringent global regulatory standards.
SK Pharmteco Capabilities Update March 2026: Small Molecule Drug Substance
Join Frank Mueller, Executive Director of Business Development, for an overview of our capabilities and global capacity spanning North America, Europe, and Asia.
Novartis Capabilities Update March 2026: Small Molecule Drug Substance
Driven by a strong commitment to quality, compliance, and operational excellence, our teams deliver reliable and scalable manufacturing solutions tailored to each partner’s unique requirements.
Agenda & Presenter Details
Visit our registration pages to see the current agenda and our list of presenting sponsors.
How can we help?
Are you a supplier looking to present at our next event?